Robert Shumaker

683 total citations
18 papers, 534 citations indexed

About

Robert Shumaker is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Robert Shumaker has authored 18 papers receiving a total of 534 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 8 papers in Molecular Biology and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Robert Shumaker's work include Cancer Immunotherapy and Biomarkers (6 papers), Endometrial and Cervical Cancer Treatments (4 papers) and Endometriosis Research and Treatment (3 papers). Robert Shumaker is often cited by papers focused on Cancer Immunotherapy and Biomarkers (6 papers), Endometrial and Cervical Cancer Treatments (4 papers) and Endometriosis Research and Treatment (3 papers). Robert Shumaker collaborates with scholars based in United States and Japan. Robert Shumaker's co-authors include Emmett V. Schmidt, Matthew H. Taylor, Corina E. Dutcus, Drew Rasco, Daniel E. Stepan, Vicky Makker, Harold Boxenbaum, Gary A. Thompson, Matthew Guo and Jean Fan and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

In The Last Decade

Robert Shumaker

18 papers receiving 523 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Robert Shumaker United States 10 212 121 97 85 49 18 534
W. Seifert Netherlands 17 172 0.8× 98 0.8× 26 0.3× 124 1.5× 28 0.6× 33 811
Shinji Kobuchi Japan 13 198 0.9× 51 0.4× 61 0.6× 122 1.4× 27 0.6× 61 529
Haixia Li China 17 74 0.3× 78 0.6× 89 0.9× 258 3.0× 42 0.9× 65 896
Onkar Singh India 13 102 0.5× 92 0.8× 61 0.6× 92 1.1× 12 0.2× 44 622
Yoko Kashida Japan 16 113 0.5× 44 0.4× 112 1.2× 296 3.5× 42 0.9× 46 739
Mun Su Chung South Korea 16 54 0.3× 201 1.7× 110 1.1× 76 0.9× 30 0.6× 44 579
Junichi Iwamoto Japan 17 307 1.4× 138 1.1× 81 0.8× 286 3.4× 67 1.4× 39 1.1k
Michiyuki Kato Japan 16 342 1.6× 121 1.0× 234 2.4× 560 6.6× 96 2.0× 45 1.0k
Alan Broughton United States 18 118 0.6× 92 0.8× 193 2.0× 231 2.7× 100 2.0× 40 956
G. H. Hottendorf United States 18 172 0.8× 161 1.3× 284 2.9× 175 2.1× 69 1.4× 44 819

Countries citing papers authored by Robert Shumaker

Since Specialization
Citations

This map shows the geographic impact of Robert Shumaker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert Shumaker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert Shumaker more than expected).

Fields of papers citing papers by Robert Shumaker

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert Shumaker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert Shumaker. The network helps show where Robert Shumaker may publish in the future.

Co-authorship network of co-authors of Robert Shumaker

This figure shows the co-authorship network connecting the top 25 collaborators of Robert Shumaker. A scholar is included among the top collaborators of Robert Shumaker based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert Shumaker. Robert Shumaker is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Shumaker, Robert, et al.. (2020). An Open-Label Phase 1 Study to Determine the Effect of Lenvatinib on the Pharmacokinetics of Midazolam, a CYP3A4 Substrate, in Patients with Advanced Solid Tumors. European Journal of Drug Metabolism and Pharmacokinetics. 45(3). 373–383. 2 indexed citations
2.
Vogelzang, Nicholas J., Marcia S. Brose, Allen Lee Cohn, et al.. (2020). Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: Final analysis of a multicentre, open-label, single-arm, phase 2 trial. Gynecologic Oncology. 159. 6–7. 2 indexed citations
3.
Vogelzang, Nicholas J., Carlos A. Encarnacion, Allen Lee Cohn, et al.. (2019). Phase Ib/II trial of lenvatinib plus pembrolizumab in urothelial cancer.. Journal of Clinical Oncology. 37(8_suppl). 11–11. 9 indexed citations
4.
Brose, Marcia S., Nicholas J. Vogelzang, Christopher DiSimone, et al.. (2019). A phase Ib/II trial of lenvatinib plus pembrolizumab in non-small cell lung cancer.. Journal of Clinical Oncology. 37(8_suppl). 16–16. 9 indexed citations
5.
Makker, Vicky, Matthew H. Taylor, Carol Aghajanian, et al.. (2019). Lenvatinib (LEN) and pembrolizumab (PEMBRO) in advanced endometrial cancer (EC). Annals of Oncology. 30. v404–v405. 6 indexed citations
6.
Taylor, Matthew H., Nicholas J. Vogelzang, Allen Lee Cohn, et al.. (2019). Phase Ib/II trial of lenvatinib plus pembrolizumab in advanced melanoma.. Journal of Clinical Oncology. 37(8_suppl). 15–15. 5 indexed citations
7.
Makker, Vicky, Drew Rasco, Nicholas J. Vogelzang, et al.. (2018). Lenvatinib + pembrolizumab in patients with advanced endometrial cancer: Updated results.. Journal of Clinical Oncology. 36(15_suppl). 5596–5596. 10 indexed citations
8.
Lee, Chung‐Han, Vicky Makker, Drew Rasco, et al.. (2018). Lenvatinib + pembrolizumab in patients with renal cell carcinoma: Updated results.. Journal of Clinical Oncology. 36(15_suppl). 4560–4560. 37 indexed citations
9.
Taylor, Matthew H., Drew Rasco, Marcia S. Brose, et al.. (2018). A phase 1b/2 trial of lenvatinib plus pembrolizumab in patients with squamous cell carcinoma of the head and neck.. Journal of Clinical Oncology. 36(15_suppl). 6016–6016. 27 indexed citations
10.
Lee, Chi‐Hang, Vicky Makker, Matthew H. Taylor, et al.. (2017). A phase 1b/2 trial of lenvatinib plus pembrolizumab in patients with renal cell carcinoma. Annals of Oncology. 28. v295–v296. 22 indexed citations
11.
Makker, Vicky, Drew Rasco, Corina E. Dutcus, et al.. (2017). A phase Ib/II trial of lenvatinib (LEN) plus pembrolizumab (Pembro) in patients (Pts) with endometrial carcinoma.. Journal of Clinical Oncology. 35(15_suppl). 5598–5598. 26 indexed citations
12.
Sachdev, Perminder S., et al.. (2017). Abstract 5050: Pharmacodynamic and pharmacokinetic relationship of single agent E7449 in patients with advanced solid tumors or B-cell malignancies. Cancer Research. 77(13_Supplement). 5050–5050. 1 indexed citations
13.
Taylor, Matthew H., Corina E. Dutcus, Emmett V. Schmidt, et al.. (2016). A phase 1b trial of lenvatinib (LEN) plus pembrolizumab (PEM) in patients with selected solid tumors. Annals of Oncology. 27. vi267–vi267. 23 indexed citations
14.
Shumaker, Robert, et al.. (2014). Evaluation of the effects of formulation and food on the pharmacokinetics of lenvatinib (E7080) in healthy volunteers. International Journal of Clinical Pharmacology and Therapeutics. 52(4). 284–291. 38 indexed citations
15.
Shumaker, Robert, et al.. (2012). 119 Effect of Ketoconazole Coadministration On Lenvatinib (E7080) Exposure in Healthy Volunteers. European Journal of Cancer. 48. 37–37. 2 indexed citations
16.
17.
Shumaker, Robert, Harold Boxenbaum, & Gary A. Thompson. (1988). ABSPLOTS: A LOTUS 123 Spreadsheet for Calculating and Plotting Drug Absorption Rates. Pharmaceutical Research. 5(4). 247–248. 27 indexed citations
18.
Shumaker, Robert. (1986). PKCALC: A Basic Interactive Computer Program for Statistical and Pharmacokinetic Analysis of Data. Drug Metabolism Reviews. 17(3-4). 331–348. 276 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by W. Seifert Breakdown of academic impact, for papers by Shinji Kobuchi Breakdown of academic impact, for papers by Haixia Li Breakdown of academic impact, for papers by Onkar Singh Breakdown of academic impact, for papers by Yoko Kashida Breakdown of academic impact, for papers by Mun Su Chung Breakdown of academic impact, for papers by Junichi Iwamoto Breakdown of academic impact, for papers by Michiyuki Kato Breakdown of academic impact, for papers by Alan Broughton Breakdown of academic impact, for papers by G. H. Hottendorf
Rankless by CCL
2026